March 25, 2013
Daiichi Sankyo President and CEO Joji Nakayama With the loss of exclusivity (LOE) for its flagship angiotensin receptor blocker olmesartan (Japanese brand name: Olmetec) looming, Daiichi Sankyo is weighing strategies to overcome a “patent cliff” that would ensue. “Our challenge...read more